Outlook Therapeutics receives positive CHMP opinion from European Medicines Agency for bevacizumab
The positive opinion concerns authorization of bevacizumab gamma (ONS-5010/LYTENAVA), a formulation of bevacizumab for treatment of wet age-related macular degeneration (wet AMD).